Research Study to Compare Semaglutide Tablets With Empagliflozin Tablets Taken Once Daily in People With Type 2 Diabetes and Obesity

NCT05444153 · clinicaltrials.gov ↗

PHASE3

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Sponsor decision

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG: Semaglutide
DRUG: Empagliflozin

Sponsor

Novo Nordisk A/S